MKI67 and neoplasm: Letrozole plus mTOR inhibitor everolimus results in a better progression free survival in patients with breast cancer, accompanied by decreases in Ki-67 index and tumor-infiltrating regulatory T cells, and an increase in tumor-specific CD8+ T cells [18–20].